| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/04/2000 | US6046030 For the treatment of neurological disorders such as alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease, among others and diagnostic assays for such |
| 04/04/2000 | US6046025 Expression of heterologous proteins in drosophila cells |
| 04/04/2000 | US6046009 Diagnosis and treatment of glaucoma |
| 04/04/2000 | US6045999 Transcription factor E2F-4 |
| 04/04/2000 | US6045806 Babesia vaccine |
| 04/04/2000 | US6045805 Oligosaccharide derived from an antigenic polysaccharide obtained from a pathogenic agent |
| 04/04/2000 | US6045803 Administering to an avian a recombinant herpesvirus of turkeys for expressing an antigenic polypeptide to treat viral diseases |
| 04/04/2000 | US6045802 Antitumor agents treating cancer |
| 04/04/2000 | US6045799 Inducing infertility in a mammal by administering a recombinant chimeric protein in a diluent, adjuvant or carrier |
| 04/04/2000 | US6045798 Membrane-associated immunogens of mycobacteria |
| 04/04/2000 | US6045796 Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease |
| 04/04/2000 | US6045795 Methods and compositions for ameliorating the symptoms of sepsis |
| 04/04/2000 | US6045792 Human proteins kinases |
| 04/04/2000 | US6045790 A cell culture product from an equine influenza virus and the human influenza virus a/puerto rico/ 8/34, comprises rna encoding for at least one neuraminidase or haemagglutinin surface antigen and matrix protein |
| 04/04/2000 | US6045789 Bystander effect tumoricidal therapy by expressing an HSV-tk gene |
| 04/04/2000 | US6045774 Diagnosis of cancer and other disorders |
| 04/04/2000 | CA2246162C Modulation of th1/th2 cytokine expression by ribavirin.rtm. and ribavirin.rtm. analogs in activated t-lymphocytes |
| 04/04/2000 | CA2173878C Polynucleotide for treating systemic lupus erythematosus |
| 04/04/2000 | CA2031129C Chimeric antibody for detection and therapy of infectious and inflammatory lesions |
| 03/30/2000 | WO2000017382A1 Methods and compositions relating to bone-derived growth factor-like polypeptides |
| 03/30/2000 | WO2000017373A1 Recombinant celo virus and celo virus dna |
| 03/30/2000 | WO2000017370A1 HUMAN COMPLEMENT C3-DEGRADING POLYPEPTIDE FROM $i(STREPTOCOCCUS PNEUMONIAE) |
| 03/30/2000 | WO2000017362A1 Human interleukin-b50, therapeutic uses |
| 03/30/2000 | WO2000017354A1 Human isre-binding protein |
| 03/30/2000 | WO2000017344A1 RESPONSE REGULATOR $i(CaSSK1) |
| 03/30/2000 | WO2000017232A2 Regulatory protein from human keratinocytes |
| 03/30/2000 | WO2000017222A1 31 human secreted proteins |
| 03/30/2000 | WO2000016808A2 Antibody directed enzyme prodrug therapy (edept) with glucoronidase |
| 03/30/2000 | WO2000016805A1 Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers and testicular cancer |
| 03/30/2000 | WO2000016804A1 METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
| 03/30/2000 | WO2000016802A1 Hepatitis b core antigen nucleic acid vaccine |
| 03/30/2000 | WO2000016801A1 Methods of downmodulating the immune response to therapeutic proteins |
| 03/30/2000 | WO2000016746A2 Immunogenic liposome compositions |
| 03/30/2000 | WO2000016708A1 Methods and systems for treating breast tissue |
| 03/30/2000 | WO2000009711A8 ISOLATED AND PURIFIED HUMAN SOLUBLE GUANYLYLCYCLASE α1/β1 (hsGCα1/β1) |
| 03/30/2000 | WO2000002913B1 Chemotaxis-inhibiting protein of staphylococcus (chips) and its use |
| 03/30/2000 | WO2000002584A3 Cancer treatment methods using antibodies to aminophospholipids |
| 03/30/2000 | WO2000000614A9 NOVEL ANTIGENS OF $i(HELICOBACTER PYLORI) |
| 03/30/2000 | WO1999067393A3 Aav scleroprotein, production and use thereof |
| 03/30/2000 | WO1999049892A3 Use of active p40 conjugates for nasal delivery |
| 03/30/2000 | WO1999042477A3 Transporter protein for saccharide-coupled medicaments |
| 03/30/2000 | WO1999040932A9 Mixed micellar pharmaceutical delivery system and method of preparation |
| 03/30/2000 | DE19859115A1 Verwendung von Tumorzellen zeitversetzt in Kombination mit intakten Antikörpern zur Immunisierung Using time delay of tumor cells in combination with intact antibodies for immunization |
| 03/30/2000 | CA2344657A1 Human isre-binding protein |
| 03/30/2000 | CA2344440A1 Antibody directed enzyme prodrug therapy (edept) with glucoronidase |
| 03/30/2000 | CA2344100A1 31 human secreted proteins |
| 03/30/2000 | CA2343931A1 Human complement c3-degrading polypeptide from streptococcus pneumoniae |
| 03/30/2000 | CA2343918A1 Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers and testicular cancer |
| 03/30/2000 | CA2343916A1 Methods of downmodulating the immune response to therapeutic proteins |
| 03/30/2000 | CA2343052A1 Methods of treating ige-associated disorders and compositions for use therein |
| 03/30/2000 | CA2342957A1 Regulatory protein from human keratinocytes |
| 03/30/2000 | CA2339866A1 Recombinant celo virus and celo virus dna |
| 03/30/2000 | CA2283540A1 Anti-fas antibodies |
| 03/29/2000 | EP0988862A2 Formulation for use in immunisation |
| 03/29/2000 | EP0988380A1 Translational regulator initiation factor 4e-binding protein |
| 03/29/2000 | EP0988379A1 Ldl-receptor |
| 03/29/2000 | EP0988370A1 Electrospraying apparatus and method for introducing material into cells |
| 03/29/2000 | EP0988321A2 B7-binding molecules for treating immune diseases |
| 03/29/2000 | EP0988318A2 Human extracellular matrix proteins |
| 03/29/2000 | EP0988063A2 Process for reducing the concentration of viral and molecular pathogens in a biological material |
| 03/29/2000 | EP0988061A1 Methods for delivering bioactive agents |
| 03/29/2000 | EP0988054A1 Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis |
| 03/29/2000 | EP0988053A1 Purified saponins as oral adjuvants |
| 03/29/2000 | EP0988052A2 An influenza enveloped dna vaccine |
| 03/29/2000 | EP0988051A1 Lyme combination compositions and uses |
| 03/29/2000 | EP0988049A2 Pharmaceutical composition for treating hepatitis b virus (hbv) infection |
| 03/29/2000 | EP0777689B1 Use of cytadherence peptides for use in modifying mutual adhesion among eukaryotic cells |
| 03/29/2000 | EP0732936B1 Adjuvant for antigens, process for producing the same and its use |
| 03/29/2000 | EP0697891B1 Polyoxime compounds and their preparation |
| 03/29/2000 | EP0596959B1 Self-adjuvanting peptide vaccine delivery system and production thereof |
| 03/29/2000 | CN1249002A Component of bromelain |
| 03/29/2000 | CN1248921A Methods of therapeutic administration of anti-CD40L compounds |
| 03/29/2000 | CN1248472A Application of ouabin polyclonal antibody in preparation of medicine for curing hypertension |
| 03/29/2000 | CN1248471A Vero cell encephalitis B inactivated vaccine and preparation process thereof |
| 03/29/2000 | CN1050836C Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates preparation process |
| 03/28/2000 | US6043389 Hydroxy and ether-containing oxyalkylene esters and uses thereof |
| 03/28/2000 | US6043347 Compositions and methods for treating viral infections |
| 03/28/2000 | US6043346 Antibody that binds to a tub polypeptide |
| 03/28/2000 | US6043343 Amino acid sequence; for diagnosis and prevention of cancer and tumors; anticarcinogenic/antitumor agents; for screening compounds which bind to polypeptide |
| 03/28/2000 | US6043339 Heterologous complex of polypeptides or nucleic acids which are linked to an importation competent signal peptide and to a nuclear localization peptide; for peptide and gene therapy and antisense agents |
| 03/28/2000 | US6043085 Nucleotide and amino acid sequences; for treatment of infections/bactericides |
| 03/28/2000 | US6043081 Expression vectors encoding recombinant proteins comprising a VPR/VPX virion incorporation domain for targeting into HIV-1 or HIV-2 virions |
| 03/28/2000 | US6043071 GlmU |
| 03/28/2000 | US6043069 Catalytic antibodies and a method of producing same |
| 03/28/2000 | US6043056 Amino acid sequences; for diagnosis, treatment, and prevention of blood, karyotypic, and nervous system disorders |
| 03/28/2000 | US6043054 Polynucleotides encoding a novel GABA BP polypeptide |
| 03/28/2000 | US6043053 Wnt-3 polynucleotides |
| 03/28/2000 | US6042838 immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA) |
| 03/28/2000 | US6042836 HIV envelope polypeptides |
| 03/28/2000 | US6042835 Prototype FelV isolates for use in disease models and vaccines |
| 03/28/2000 | US6042833 Cellular internalization of pIgR stalk and associated ligands |
| 03/28/2000 | US6042832 Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins |
| 03/28/2000 | US6042831 Epitopes of the hiv virus gp160 protein, is immunologically homologous to epitopes of the protein family of the human major histocompatiblity complex, used for diagnosis and immunization |
| 03/28/2000 | US6042830 Viral agent associated with mystery swine disease |
| 03/28/2000 | US6042827 Anti-idiotypic antibody induction of anti-tumor response |
| 03/28/2000 | US6042826 Administering intrathecally or intralesionally a therapeutically effective amount of a fas-crosslinking component selected from an agonsit antihuman fas monoclonal antibody, anti-human fas bid fragments, or soluble fas-ligand |
| 03/28/2000 | US6042825 A parasitic helminth asparaginase proteins; parasitic helminth asparaginase nucleic acid molecules that codes such asparaginase proteins |
| 03/28/2000 | US6042824 Combining the substrate and a crosslinked enzyme crystal formulation containing a crosslinked enzyme and a surfactant which acts upon the substrate in presence of organic solvent or aqueous-organic solvent to form a product |
| 03/28/2000 | US6042820 Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| 03/28/2000 | CA2140531C Method of increasing expression of viral proteins |